Literature DB >> 12403352

Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction.

Vincent Hurez1, Robin D Hautton, James Oliver, R James Matthews, Casey K Weaver.   

Abstract

Technologies for transfer of exogenous genes into primary T cells have been limited until recently. The introduction of new approaches for gene transfer via different viral vectors has expanded the options for genetic manipulation of primary T cells and has provided powerful tools for studies of T cell activation and differentiation. We provide a brief overview of the systems currently available and contrast the advantages and disadvantages of each. We also describe a new transgenic model that enables highly efficient gene delivery into primary T cells by nonreplicating adenoviral vectors.

Mesh:

Substances:

Year:  2002        PMID: 12403352     DOI: 10.1385/ir:26:1-3:131

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  79 in total

1.  Lentivirus vector gene expression during ES cell-derived hematopoietic development in vitro.

Authors:  I Hamaguchi; N B Woods; I Panagopoulos; E Andersson; H Mikkola; C Fahlman; R Zufferey; L Carlsson; D Trono; S Karlsson
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 2.  Retroviral vectors.

Authors:  A D Miller
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

3.  A mouse model for adenovirus gene delivery.

Authors:  T Tallone; S Malin; A Samuelsson; J Wilbertz; M Miyahara; K Okamoto; L Poellinger; L Philipson; S Pettersson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

4.  High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes.

Authors:  B A Bunnell; L M Muul; R E Donahue; R M Blaese; R A Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

5.  Lentiviral and murine retroviral transduction of T cells for expression of human CD40 ligand.

Authors:  S C Barry; J Seppen; N Ramesh; J L Foster; K Seyama; H D Ochs; J V Garcia; W R Osborne
Journal:  Hum Gene Ther       Date:  2000-01-20       Impact factor: 5.695

6.  Expression of a human coxsackie/adenovirus receptor transgene permits adenovirus infection of primary lymphocytes.

Authors:  M R Schmidt; B Piekos; M S Cabatingan; R T Woodland
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

7.  Adenoviral-mediated gene transfer in lymphocytes.

Authors:  R P Leon; T Hedlund; S J Meech; S Li; J Schaack; S P Hunger; R C Duke; J DeGregori
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

8.  Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs.

Authors:  Y Yang; Q Su; J M Wilson
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

9.  Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes.

Authors:  R Philip; E Brunette; L Kilinski; D Murugesh; M A McNally; K Ucar; J Rosenblatt; T B Okarma; J S Lebkowski
Journal:  Mol Cell Biol       Date:  1994-04       Impact factor: 4.272

10.  Integration of murine leukemia virus DNA depends on mitosis.

Authors:  T Roe; T C Reynolds; G Yu; P O Brown
Journal:  EMBO J       Date:  1993-05       Impact factor: 11.598

View more
  2 in total

1.  Distinct regulation of integrin-dependent T cell conjugate formation and NF-kappa B activation by the adapter protein ADAP.

Authors:  Brandon J Burbach; Rupa Srivastava; Ricardo B Medeiros; William E O'Gorman; Erik J Peterson; Yoji Shimizu
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

2.  Generation of CD4CreER(T²) transgenic mice to study development of peripheral CD4-T-cells.

Authors:  Katayoun Aghajani; Shilpa Keerthivasan; Yu Yu; Fotini Gounari
Journal:  Genesis       Date:  2012-09-12       Impact factor: 2.487

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.